NeOnc’s Clinical Story Is Now the Main Event

DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100’s clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer?

On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint, with 48.9% six-month progression-free survival versus a pre-specified 20% benchmark, producing a reported p-value of 0.0047. NeOnc also reported median overall survival of 26.09 months, with 86.7% of patients alive at six months. Five of the 24 patients remained on treatment, including one partial response continuing beyond 114 days.